ReviewBritish journal of cancer2026
Revisiting retinoic acid in AML therapy: mechanisms of action and rational combination strategies.
Review in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
All-trans retinoic acid (ATRA), a bioactive vitamin A derivative, regulates cellular differentiation by activating retinoic acid receptors (RARs). While ATRA has revolutionised acute promyelocytic leukaemia (APL) treatment, its efficacy in non-APL acute myeloid leukaemia (AML) remains limited due to intrinsic resistance mechanisms, including aberrant epigenetic states and signalling pathways. This review summarises recent mechanistic and translational advances in ATRA-based combination therapies that target differentiation blockade. We focus on the interplay between retinoic acid signalling, chromatin regulation, cell cycle control, and apoptosis, with a particular emphasis on AML. Epigenetic regulators, including the lysine-specific demethylase LSD1 (KDM1A) and the acetyltransferase GCN5 (KAT2A), together with dysregulated cell cycle control and oncogenic signalling, including Fms-like tyrosine kinase 3 (FLT3) and phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR), sustain proliferation and block differentiation. Targeting these pathways with specific inhibitors synergises with ATRA to restore myeloid maturation, induce cell cycle arrest, and promote apoptosis. Future studies should identify predictive biomarkers for patient stratification to translate these synergistic concepts into clinical benefit.
Identifiers
42393459What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.